Loading
Five weeks of carboplatin-paclitaxel with radiotherapy before oesophagectomy lengthened median survival from 24 to 49 months in oesophageal cancer compared with surgery alone, with a complete pathological response in almost half of squamous cancers.
Phase 3 trial of 366 patients with resectable oesophageal or junctional cancer (75 percent adenocarcinoma) randomised to weekly carboplatin-paclitaxel with 41.4 Gy radiotherapy followed by surgery, or surgery alone.
Median overall survival was 49.4 versus 24.0 months (hazard ratio 0.657), complete resection 92 versus 69 percent and pathological complete response 29 percent overall (49 percent in squamous cell carcinoma); the ten-year update confirmed the benefit.
CROSS chemoradiotherapy is a standard for locally advanced oesophageal cancer, particularly squamous cell carcinoma; for adenocarcinoma, perioperative FLOT is now often preferred after ESOPEC.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares CROSS, Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.